A Phase 1 Study of Patient-Derived Multi-Tumor Associated Antigen Specific T Cells (MT-601) Administered to Patients with Metastatic Pancreatic Cancer following frontline FOLFIRINOX

ABSTRACT

Pancreatic cancer (PC) is an orphan disease with a 5-year relative survival of 11.5% and relative survival for

metastatic PC of only 3.1%. Although surgical resection provides the best curative option, 200 patients with various cancer types. Therefore, Marker

Therapeutics proposes to use MT-601, an improved mTAA-specific T cell product for PC in order to improve

patient outcomes. Combining MT-601 with front-line FOLFIRINOX chemotherapy may overcome current

limitations of immunotherapy in PC.

This grant proposes a Phase 1, open-label study to evaluate safety and efficacy of MT-601 combined with front-

line chemotherapy in metastatic PC patients. Specific Aim 1 assesses primary and secondary safety and

efficacy outcomes in PC patients treated with front-line chemotherapy (FOLFIRINOX) in combination with MT-

601. Specific Aim 2 will correlate biological characteristics in the product profile with clinical safety and efficacy

outcomes. Successful completion of this grant will provide clinical proof of concept for MT-601 as a treatment for

PC patients and support future clinical trials leading to future BLA filing and commercial approval of MT-601.